A
TRVI icon

AJOVista’s Trevi Therapeutics TRVI Stock Holding History

AJOVista’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$38.4K Buy
+11,495
New +$34.2K 0.16% 103

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

AJOVista's TRVI Position: Q3 2024 in Review

AJOVista opened a new position in Trevi Therapeutics (TRVI) in Q3 2024: 11,495 shares worth $38.4K. The stake represents 0.16% of the portfolio and ranks #103 among its holdings.

93 funds tracked by Wall St. Rank hold TRVI as of Q3 2024.

  • AJOVista held 11,495 shares of Trevi Therapeutics worth $38.4K as of Q3 2024.
  • Trevi Therapeutics was a new AJOVista position in Q3 2024.
  • Trevi Therapeutics made up 0.16% of AJOVista's portfolio in Q3 2024, its #103 holding.
  • 93 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2024.

Based on AJOVista's 13F filing for Q3 2024, filed 12 Nov 2024.